Vertex Pharmaceuticals Cash Flow Statement
NASDAQ: VRTXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vertex Pharmaceuticals free cash flow
In fiscal 2025, Vertex Pharmaceuticals generated $3.63 billion of operating cash flow and spent $437.6 million on capital expenditures. That left free cash flow of $3.19 billion, a free-cash-flow margin of 26.6% of revenue. Vertex Pharmaceuticals returned $2.02 billion to shareholders through share repurchases, equal to 63% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Vertex Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 3.95B | -535.60M | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.09B | 91.64M | -84.03M |
| Net Income growth (YoY) | — | -114.80% | +8.96% | +41.84% | -13.63% | +130.42% | -43.62% | +2177.63% | — | — |
| Depreciation & Amortization | 209.80M | 207.20M | 181.30M | 148.30M | 125.60M | 109.50M | 106.90M | 72.42M | 61.40M | 61.40M |
| Stock-Based Compensation | 685.90M | 698.50M | 581.20M | 491.30M | 441.40M | 429.50M | 360.50M | 325.05M | 293.24M | 240.62M |
| Change in Working Capital | -1.08B | -727.70M | -695.10M | -201.70M | -410.60M | -176.60M | -239.00M | 64.54M | -83.43M | 577.00K |
| Operating Cash Flow | 3.63B | -492.60M | 3.54B | 4.13B | 2.64B | 3.25B | 1.57B | 1.27B | 844.94M | 236.10M |
| Capital Expenditures | -437.60M | -297.70M | -200.40M | -204.70M | -235.00M | -259.80M | -75.40M | -95.45M | -99.42M | -56.56M |
| Investing Cash Flow | -945.40M | -3.77B | -3.14B | -321.10M | -340.90M | 99.40M | -1.24B | -202.16M | -483.33M | 51.24M |
| Share Repurchases | -2.02B | -1.18B | -427.60M | 0 | -1.43B | -539.10M | -186.00M | -350.04M | 0 | 0 |
| Financing Cash Flow | -2.26B | -1.49B | -562.20M | -67.70M | -1.48B | -505.30M | 126.80M | -71.22M | 68.40M | 133.27M |
| Net Change in Cash | 515.60M | -5.80B | -139.70M | 3.71B | 811.20M | 2.87B | 462.40M | 990.73M | 435.82M | 415.95M |
| Free Cash Flow | 3.19B | -790.30M | 3.34B | 3.93B | 2.41B | 2.99B | 1.49B | 1.17B | 745.52M | 179.54M |
This table shows 10 annual periods of Vertex Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VRTX's reporting calendar. What is a cash flow statement?